273 related articles for article (PubMed ID: 36394204)
21. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
[TBL] [Abstract][Full Text] [Related]
22. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
23. Classifying Melanoma by TERT Promoter Mutational Status.
Shaughnessy M; Njauw CN; Artomov M; Tsao H
J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705
[TBL] [Abstract][Full Text] [Related]
24. Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines.
Hu K; Ghandi M; Huang FW
Elife; 2021 Sep; 10():. PubMed ID: 34486523
[TBL] [Abstract][Full Text] [Related]
25. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
26. Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas.
Butler KS; Hines WC; Heaphy CM; Griffith JK
Cancer Med; 2012 Oct; 1(2):165-75. PubMed ID: 23342266
[TBL] [Abstract][Full Text] [Related]
27. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
[TBL] [Abstract][Full Text] [Related]
28.
Patel B; Taiwo R; Kim AH; Dunn GP
Neurooncol Adv; 2020; 2(1):vdaa025. PubMed ID: 32226942
[TBL] [Abstract][Full Text] [Related]
29. Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma.
Jendrzejewski J; Tomsic J; Lozanski G; Labanowska J; He H; Liyanarachchi S; Nagy R; Ringel MD; Kloos RT; Heerema NA; de la Chapelle A
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1876-80. PubMed ID: 21900378
[TBL] [Abstract][Full Text] [Related]
30. TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma.
Chun-On P; Hinchie AM; Beale HC; Gil Silva AA; Rush E; Sander C; Connelly CJ; Seynnaeve BKN; Kirkwood JM; Vaske OM; Greider CW; Alder JK
Science; 2022 Nov; 378(6620):664-668. PubMed ID: 36356143
[TBL] [Abstract][Full Text] [Related]
31. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
32. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
[TBL] [Abstract][Full Text] [Related]
33. The role of telomeres and telomerase reverse transcriptase isoforms in pluripotency induction and maintenance.
Teichroeb JH; Kim J; Betts DH
RNA Biol; 2016 Aug; 13(8):707-19. PubMed ID: 26786236
[TBL] [Abstract][Full Text] [Related]
34. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
Jin A; Xu J; Wang Y
Medicine (Baltimore); 2018 Jul; 97(29):e11548. PubMed ID: 30024548
[TBL] [Abstract][Full Text] [Related]
35. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
[TBL] [Abstract][Full Text] [Related]
36. P. berghei telomerase subunit TERT is essential for parasite survival.
Religa AA; Ramesar J; Janse CJ; Scherf A; Waters AP
PLoS One; 2014; 9(9):e108930. PubMed ID: 25275500
[TBL] [Abstract][Full Text] [Related]
37. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.
Wang N; Kjellin H; Sofiadis A; Fotouhi O; Juhlin CC; Bäckdahl M; Zedenius J; Xu D; Lehtiö J; Larsson C
Oncotarget; 2016 Apr; 7(16):21332-46. PubMed ID: 26870890
[TBL] [Abstract][Full Text] [Related]
38. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
39. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies.
Babizhayev MA; Yegorov YE
J Biomed Mater Res A; 2015 Dec; 103(12):3993-4023. PubMed ID: 26034007
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
